FDA Clears IND for Next-Gen Oncolytic Virus UGN-501 in NMIBC

The FDA has cleared the investigational new drug (IND) application for UGN-501, an investigational next-generation oncolytic virus in development for the treatment of patients with non–muscle invasive bladder cancer (NMIBC).¹

The clearance enables clinical investigation of the agent in a planned phase 1 study in patients with NMIBC. With initiation of the study expected in Q4 2026, the study will assess the safety, tolerability, and feasibility of intravesical administration of UGN-501 in patients with NMIBC.

"Patients with [NMIBC] continue to face a significant risk of disease recurrence despite available treatment options," said Mark Schoenberg, MD, chief medical officer of UroGen, in a news release.¹ "UGN-501 is an investigational next-generation oncolytic virus designed to selectively destroy tumor cells while generating an antitumor immune response. FDA clearance of the IND allows us to begin evaluating whether the encouraging nonclinical profile of UGN-501 can translate into a safe and meaningful therapeutic approach for patients with NMIBC. We look forward to initiating the [p]hase 1 study and advancing our efforts to develop innovative treatment options for patients with bladder cancer."

UGN-501 and the Unmet Need in NMIBC

Despite currently available treatments, NMIBC continues to present clinical challenges, particularly for patients whose disease recurs following standard treatment. With UGN-501’s clinical development soon to begin, the agent enters a treatment landscape where bladder-sparing options for BCG-unresponsive NMIBC still fall short for many patients.

A systematic review encompassing 57 studies and 2589 patients found that existing bladder-sparing salvage therapies produced an overall response rate of 52.4% (95% CI, 45.4%-59.2%) at 3 months, with response and recurrence-free rates declining over time and progression to muscle-invasive or metastatic disease occurring in an estimated 13% (95% CI, 9%-18.2%) of patients.² These figures point to a continued need for more durable and effective options.

This unmet need is central to the rationale of UGN-501 and the broader development of bladder-sparing approaches. As an oncolytic viral therapy, UGN-501’s mechanism of action involves selective replication within tumor cells, leading to direct tumor cell destruction and antitumor immune activation. The forthcoming phase 1 study will be the first to evaluate whether the effectiveness of this mechanism translates safely into the clinical setting.

Engineering Oncolytic Viruses for Precision Cancer Treatment

REFERENCES

1. UroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer. News release. July 8, 2026. Accessed July 9, 2026. https://tinyurl.com/2w5aupbn

2. D'Andrea D, Mostafid H, Gontero P, et al. Unmet Need in Non-muscle-invasive Bladder Cancer Failing Bacillus Calmette-Guérin Therapy: A Systematic Review and Cost-effectiveness Analyses from the International Bladder Cancer Group. Eur Urol Oncol. 2025;8(1):216-229. doi:10.1016/j.euo.2024.10.012